gc022
Cell therapyexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 17, 2019 (NCT03825731)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD22Immunity, passive
CD22 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04626908 | Phase 1/Phase 2 (Phase 2) | Nov 20, 2020 | Gracell Biotechnology Ltd., Zhejiang University |
| NCT04412174 | Early Phase 1 (Phase 1) | Jun 30, 2020 | Gracell Biotechnology Ltd., Ludaopei Hospital |
| NCT04129099 | Early Phase 1 (Phase 1) | Nov 30, 2019 | Gracell Biotechnology Ltd., Ludaopei Hospital |
| NCT03825731 | Early Phase 1 (Phase 1) | Jan 17, 2019 | Gracell Biotechnology Ltd., Ludaopei Hospital |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gracell Biotechnology Ltd. | For profit | 4 | 0 | 2 | 2019 |
| Ludaopei Hospital | Academic/Hospital | 3 | 3 | 1 | 2019 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1